Samer Gawrieh1, Kathryn E Harlow2, Francis Pike3, Katherine P Yates4, Laura A Wilson4, Oscar W Cummings5, William M Rosenberg6, Naga Chalasani7, Jean P Molleston2. 1. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN. Electronic address: sgawrieh@iu.edu. 2. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Riley Hospital for Children at Indiana University School of Medicine, Indianapolis, IN. 3. Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN. 4. Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD. 5. Department of Pathology, Indiana University School of Medicine, Indianapolis, IN. 6. Division of Medicine, University College London, London, UK. 7. Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Abstract
OBJECTIVES: To study the diagnostic performance of the enhanced liver fibrosis score (ELF) for detecting different stages of fibrosis and its usefulness in detecting histologic response to vitamin E or metformin in children with nonalcoholic fatty liver disease who participated in the Vitamin E or Metformin for the Treatment Of NAFLD In Children (TONIC) trial. STUDY DESIGN: ELF was measured at baseline and weeks 24, 48, and 96 on sera from 166 TONIC participants. Associations between ELF with baseline and end of trial (EOT) fibrosis stages and other histologic features were assessed using χ2 tests and logistic regression models. RESULTS: ELF was significantly associated with severity of fibrosis at baseline and EOT. ELF areas under the curve for discriminating patients with clinically significant and advanced fibrosis were 0.70 (95% CI, 0.60-0.80) and 0.79 (95% CI, 0.69-0.89), respectively. A 1-unit decrease in ELF at EOT was associated with overall histologic improvement (OR, 1.86; 95% CI, 1.11-3.14; P = .02), resolution of steatohepatitis (OR, 1.88; 95% CI, 1.09-3.25; P = .02), improvement in steatosis grade (OR, 1.76; 95% CI, 1.06-2.82; P = .03), and hepatocellular ballooning (OR, 1.79; 95% CI, 1.06-3.00; P = .03), but not with improvement in fibrosis stage (OR, 1.26; 95% CI, 0.78-2.03; P = .34). CONCLUSIONS: ELF was associated with fibrosis stage in children who participated in TONIC. Although not associated with improvement in fibrosis, a decrease in ELF at EOT was associated with Nonalcoholic Steatohepatitis resolution and improvement in nonalcoholic fatty liver disease histology. ELF may be a useful noninvasive test to monitor treatment response in children with nonalcoholic fatty liver disease.
OBJECTIVES: To study the diagnostic performance of the enhanced liver fibrosis score (ELF) for detecting different stages of fibrosis and its usefulness in detecting histologic response to vitamin E or metformin in children with nonalcoholic fatty liver disease who participated in the Vitamin E or Metformin for the Treatment Of NAFLD In Children (TONIC) trial. STUDY DESIGN: ELF was measured at baseline and weeks 24, 48, and 96 on sera from 166 TONIC participants. Associations between ELF with baseline and end of trial (EOT) fibrosis stages and other histologic features were assessed using χ2 tests and logistic regression models. RESULTS: ELF was significantly associated with severity of fibrosis at baseline and EOT. ELF areas under the curve for discriminating patients with clinically significant and advanced fibrosis were 0.70 (95% CI, 0.60-0.80) and 0.79 (95% CI, 0.69-0.89), respectively. A 1-unit decrease in ELF at EOT was associated with overall histologic improvement (OR, 1.86; 95% CI, 1.11-3.14; P = .02), resolution of steatohepatitis (OR, 1.88; 95% CI, 1.09-3.25; P = .02), improvement in steatosis grade (OR, 1.76; 95% CI, 1.06-2.82; P = .03), and hepatocellular ballooning (OR, 1.79; 95% CI, 1.06-3.00; P = .03), but not with improvement in fibrosis stage (OR, 1.26; 95% CI, 0.78-2.03; P = .34). CONCLUSIONS: ELF was associated with fibrosis stage in children who participated in TONIC. Although not associated with improvement in fibrosis, a decrease in ELF at EOT was associated with Nonalcoholic Steatohepatitis resolution and improvement in nonalcoholic fatty liver disease histology. ELF may be a useful noninvasive test to monitor treatment response in children with nonalcoholic fatty liver disease.
Authors: Samer Gawrieh; Darly M Knoedler; Kia Saeian; James R Wallace; Richard A Komorowski Journal: Ann Diagn Pathol Date: 2010-11-24 Impact factor: 2.090
Authors: Julie Parkes; Paul Roderick; Scott Harris; Christopher Day; David Mutimer; Jane Collier; Martin Lombard; Graeme Alexander; John Ramage; Geoffrey Dusheiko; Mark Wheatley; Carol Gough; Alastair Burt; William Rosenberg Journal: Gut Date: 2010-07-30 Impact factor: 23.059
Authors: Elizabeth L Yu; Shahrokh Golshan; Kathryn E Harlow; Jorge E Angeles; Janis Durelle; Nidhi P Goyal; Kimberly P Newton; Mary Catherine Sawh; Jonathan Hooker; Ethan Z Sy; Michael S Middleton; Claude B Sirlin; Jeffrey B Schwimmer Journal: J Pediatr Date: 2018-12-14 Impact factor: 4.406
Authors: Arun J Sanyal; Stephen A Harrison; Vlad Ratziu; Manal F Abdelmalek; Anna Mae Diehl; Stephen Caldwell; Mitchell L Shiffman; Raul Aguilar Schall; Catherine Jia; Bryan McColgan; C Stephen Djedjos; John G McHutchison; G Mani Subramanian; Robert P Myers; Zobair Younossi; Andrew J Muir; Nezam H Afdhal; Jaime Bosch; Zachary Goodman Journal: Hepatology Date: 2019-05-28 Impact factor: 17.425
Authors: Samer Gawrieh; Laura A Wilson; Katherine P Yates; Oscar W Cummings; Eduardo Vilar-Gomez; Veeral Ajmera; Kris V Kowdley; William M Rosenberg; James Tonascia; Naga Chalasani Journal: Hepatol Commun Date: 2021-02-05
Authors: Imeke Goldschmidt; André Di Nanni; Carolin Streckenbach; Kerstin Schnell; Thomas Danne; Ulrich Baumann Journal: Biomed Res Int Date: 2015-07-26 Impact factor: 3.411